Effect of Pioglitazone on Serum Advanced Glycosylation End Product Peptide and Monocyte Chemoattractant Protein-1 in Type 2 Diabetic Patients

孙子林,任晓妹,金晖,弓玉祥,李丽,张林,刘必成,刘乃丰,戴德哉

DOI: https://doi.org/10.3969/j.issn.0253-3685.2006.02.001

2006-01-01

Abstract:Objective To investigate the effect of pioglitazone on serum advanced glycosylation end products-peptide(AGE-P) and monocyte chemoattractant protein-1(MCP-1) in the patients with type 2 diabetic nephropathy.Methods Sixty type 2 diabetic patients with microalbuminuria were randomized to receive pioglitazone or glipizide XL treatment for 6 months.Serum AGE-P and MCP-1 were measured by flow injection assay and ELISA respectively.Results Serum AGE-P was significantly lower after treatment in both groups than that before treatment,while it was significantly lower in pioglitazone group than that in glipizide XL group.Serum MCP-1 was significantly reduced in pioglitazone group.Conclusion Pioglitazone reduces serum AGE-P and MCP-1 levels elevated in type 2 diabetic patients with diabetic nephropathy and suggests that pioglitazone might play reno-protection role via suppression of glycosylation and inflammation.